Sign In
Buy ITCI
$131.87
+0 (+0%)
At Close: Jul 01, 2025
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
10:56am, Thursday, 08'th Aug 2024
Intra-Cellular (ITCI) reports second-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong Caplyta sales.
Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference
08:00am, Thursday, 08'th Aug 2024
NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular Therapies (ITCI) Reports Q2 Loss, Tops Revenue Estimates
09:46am, Wednesday, 07'th Aug 2024
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.45 per share a year ago.
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
07:40am, Wednesday, 07'th Aug 2024
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
07:30am, Wednesday, 07'th Aug 2024
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a 46% increase
Intra-Cellular Therapies (ITCI) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Wednesday, 31'st Jul 2024
Intra-Cellular (ITCI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast
08:00am, Wednesday, 24'th Jul 2024
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central ner
Wall Street Analysts See a 30.14% Upside in Intra-Cellular (ITCI): Can the Stock Really Move This High?
10:56am, Tuesday, 09'th Jul 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 30.1% in Intra-Cellular (ITCI). While the effectiveness of this highly sought-after metric is questionable, the
Intra-Cellular's (ITCI) Caplyta Boosts Sales, Dependence a Woe
10:55am, Monday, 24'th Jun 2024
Intra-Cellular (ITCI) is witnessing strong Caplyta sales, driven by an increasing prescription rate. However, the company is heavily dependent on Caplyta sales for growth, which is a concern.
Intra-Cellular (ITCI) Up as Second Depression Study Meets Goals
11:30am, Wednesday, 19'th Jun 2024
Intra-Cellular (ITCI) gains 10% after achieving key goals in the second late-stage study evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of MDD.
Intra-Cellular (ITCI) Soars 9.6%: Is Further Upside Left in the Stock?
07:30am, Wednesday, 19'th Jun 2024
Intra-Cellular (ITCI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price incre
Intra-Cellular Brightens MDD Outlook With Caplyta Success
02:08am, Wednesday, 19'th Jun 2024
Caplyta (lumateperone) shows significant promise as an adjunctive treatment for Major Depressive Disorder. Caplyta's unique pharmacological profile targeting serotonin, dopamine, and glutamate pathway
Intra-Cellular Therapies' Highlights Successful Data From Second Depression Study
10:37am, Tuesday, 18'th Jun 2024
Tuesday, Intra-Cellular Therapies Inc ITCI released topline results from Study 502 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disor
In Study 502, lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
Intra-Cellular Therapies to Present at the 45th Annual Goldman Sachs Global Healthcare Conference
08:00am, Monday, 10'th Jun 2024
NEW YORK, June 10, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nerv
